This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1446 entries already.
Following a €55m (US$64m) Series B financing in September, Ghent-based MRM Health today announced a strategic collaboration with the research group of Professor Emile Voest, Senior Group Leader at the Netherlands Cancer Institute (NKI) and Senior Investigator at Oncode Institute.
The European Commission has unveiled the first part of its draft for a Biotech Act, focusing on health and medical biotechnology. The proposal has won strong support from industry stakeholders, who say it addresses the urgent need for faster innovation processes to retain and develop biotech in Europe.
Sobi AB has completed the US$1.5bn acquisition of Chinese Arthrosi Therapeutics Ltd. Its lead candidate, pozdeutinurad, a URAT1 inhibitor for gout, is in pivotal global Phase-III trials, with China licensing targeting approval by 2028.
Sanofi’s tolebrutinib fails Phase III in PPMS, while FDA postpones decision on targeted therapy approval for nrSPMS.
Fida Biosystems ApS has added €5m from EIFO and FSG to an ongoing Series A financing to scale its Flow-Induced Dispersion Analysis platform, advancing in-solution biophysical analysis for drug discovery.
The German pharmaceutical association vfa has updated its ranking of the best locations for industry-sponsored clinical trials. In Europe, Spain retained its top position in 2024, followed by Australia, Germany, the UK, and France.
Radiopharmaceuticals specialist RadioMedix Inc has secured five-year Thorium-228 supply from Van Overeem, strengthening 212Pb production and Targeted Alpha Therapy pipeline development.
Danish Zealand Pharma A/S partners with Chinese start-up OTR Therapeutics Co. Ltd to expand oral obesity pipeline in US$30m upfront deal.
Lilly’s triple weight loss combination therapy retatrutide has shown 28.7% weight loss in Phase 3, but higher discontinuations vs. tirzepatide and semaglutide.
Pfizer’s Tukysa improves progression-free survival in first-line HER2-positive breast cancer, especially in HR-negative patients, with manageable safety. Data were shown at the 2025 San Antonio Breast Cancer Symposium.